May 5, 2017 Participation at 13th Annual PEGS Boston Summit 2017
At the largest annual meeting of specialists in development of innovative biopharmaceuticals, which took place from 1st to 5th May 2017 in Boston, US, Rentschler was present with a lecture on next-generation fusion proteins.
In his presentation "Fusion protein approaches to generate biobetters - current status and future outlook" Dr. Stefan R. Schmidt, Senior Vice President Process Science and Production at Rentschler, highlighted current strategies to generate biobetters with superior properties. These biobetters typically demonstrate improved pharmacokinetics or more selective targeting. In many cases, this is achieved by fusing the therapeutic entity to other protein modules influencing plasma half-life or reducing off-target toxicity. In the presentation benefits and limits have been described as examples from the present drug development pipeline.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication